HURA — TuHURA Biosciences Share Price
0.000.00%
Last trade - 00:00- $171.23m
- $158.85m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.96 | ||
| Price to Tang. Book | 11.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -151.12% | ||
| Return on Equity | -1384.22% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. It is leveraging its Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates (APCs) and antibody-drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells (MDSCs). In addition to its innate immune agonist candidates, the Company plans to advance its VISTA-inhibiting antibody into a phase II trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML.
Directors
- Robert Hoffman PRE (57)
- Scott Praill CFO (55)
- John Liatos SVP (53)
- Dennis Brown CSO (72)
- Steven Rychnovsky VRD (62)
- Laura Johnson IND (57)
- Tamara Seymour IND (63)
- Robert Toth IND (57)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 24th, 2009
- Public Since
- July 12th, 2016
- No. of Shareholders
- 606
- No. of Employees
- 19
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 43,680,397
- Address
- 10500 University Center Dr., Suite 110, TAMPA, 33612
- Web
- https://www.kintara.com/
- Phone
- +1 8138756600
- Auditors
- Cherry Bekaert LLP
Upcoming Events for HURA
TuHURA Biosciences Inc Annual Shareholders Meeting
Q2 2025 TuHURA Biosciences Inc Earnings Release
Similar to HURA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the TuHURA Biosciences share price?
As of Today at 23:49 UTC, shares in TuHURA Biosciences are trading at $3.92. This share price information is delayed by 15 minutes.
How has the TuHURA Biosciences share price performed this year?
Shares in TuHURA Biosciences last closed at $3.92 and the price had moved by -28.75% over the past 365 days. In terms of relative price strength the TuHURA Biosciences share price has underperformed the S&P500 Index by -35.76% over the past year.
What are the analyst and broker recommendations for TuHURA Biosciences?
The overall consensus recommendation for TuHURA Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the TuHURA Biosciences dividend yield?
TuHURA Biosciences does not currently pay a dividend.
Does TuHURA Biosciences pay a dividend?
TuHURA Biosciences does not currently pay a dividend.
When does TuHURA Biosciences next pay dividends?
TuHURA Biosciences does not currently pay a dividend.
How do I buy TuHURA Biosciences shares?
To buy shares in TuHURA Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TuHURA Biosciences?
As of the previous close price of $3.92, shares in TuHURA Biosciences had a market capitalisation of $171.23m.
Where are TuHURA Biosciences shares listed?
Here are the trading details for TuHURA Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HURA
What kind of share is TuHURA Biosciences?
Based on an overall assessment of its quality, value and momentum TuHURA Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TuHURA Biosciences share price forecast for 2025?
The analyst consensus target price for shares in TuHURA Biosciences is $15.00. That is 282.65% above the last closing price of $3.92.
Analysts covering TuHURA Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.50 for the next financial year.
Find out moreWhat is the trend in the TuHURA Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TuHURA Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -35.34%.
As of the last closing price of $3.92, shares in TuHURA Biosciences were trading -23.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TuHURA Biosciences PE Ratio?
The TuHURA Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TuHURA Biosciences?
TuHURA Biosciences' management team is headed by:
- Robert Hoffman - PRE
- Scott Praill - CFO
- John Liatos - SVP
- Dennis Brown - CSO
- Steven Rychnovsky - VRD
- Laura Johnson - IND
- Tamara Seymour - IND
- Robert Toth - IND